Bank of New York Mellon Corp Buys 150 Shares of BioNTech SE (NASDAQ:BNTX)

Bank of New York Mellon Corp boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,677 shares of the company’s stock after buying an additional 150 shares during the quarter. Bank of New York Mellon Corp’s holdings in BioNTech were worth $419,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BNTX. Union Bancaire Privee UBP SA bought a new stake in shares of BioNTech in the fourth quarter valued at about $282,000. Flossbach Von Storch SE raised its holdings in shares of BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after purchasing an additional 47,236 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of BioNTech in the 4th quarter valued at about $1,118,000. AlphaCentric Advisors LLC purchased a new stake in shares of BioNTech in the 4th quarter worth approximately $168,000. Finally, Vontobel Holding Ltd. boosted its stake in shares of BioNTech by 24.6% during the fourth quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company’s stock valued at $2,437,000 after purchasing an additional 4,227 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on BNTX. BMO Capital Markets boosted their price target on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup assumed coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target on the stock. Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Finally, Morgan Stanley lowered their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Price Performance

BioNTech stock opened at $94.95 on Friday. The business has a 50 day simple moving average of $111.41 and a 200-day simple moving average of $113.55. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $22.79 billion, a PE ratio of -45.21 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period last year, the firm earned $1.90 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities analysts predict that BioNTech SE will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.